Innoviva, Inc. reported a total revenue of $119.6 million for the second quarter of 2026, marking a 19% increase from $100.3 million in the same period last year. The revenue growth was driven by a combination of stable royalty income and significant increases in net product sales. Royalty revenue from GlaxoSmithKline (GSK) was $59.8 million, while net product sales reached $51.8 million, reflecting a 46% increase compared to $35.5 million in the second quarter of 2025. The company’s income from operations was $50.9 million, up from $48.8 million a year earlier, indicating effective cost management alongside revenue growth.
In terms of profitability, Innoviva reported a net loss of $83.4 million, or $1.14 per share, primarily due to unfavorable changes in the fair value of equity and long-term investments, which totaled a loss of $161 million. This contrasts sharply with a net income of $63.7 million in the second quarter of 2025. The company’s cash and cash equivalents stood at $570.4 million as of June 30, 2026, with receivables from royalties and product sales totaling $110.6 million, a 25% increase year-over-year.
Strategically, Innoviva has made significant strides in expanding its product offerings and market reach. The company entered into an exclusive distribution and licensing agreement with Dr. Reddy’s Laboratories for the commercialization of XACDURO® in various regions, including South and Central America. Additionally, Innoviva launched Nortiva Bio, a subsidiary focused on advancing its proprietary LYNX™ long-acting oral drug delivery platform, which aims to improve patient adherence through less frequent dosing regimens.
Operationally, the company has seen a notable increase in its workforce and product adoption rates. The total number of employees has grown as Innoviva expands its sales force to support its marketed products. The company’s strategic healthcare investments, valued at $669.5 million, include a significant stake in Armata Pharmaceuticals, which has been a key contributor to the fluctuations in fair value reported in the financial results. Looking ahead, Innoviva remains focused on leveraging its diversified portfolio to drive long-term shareholder value, with plans to continue its share repurchase program and support its strategic healthcare assets.
About Innoviva, Inc.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov